정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
107 | Recruiting | Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia | Cytokine Storm | Biological: Injection of Secretome-MSCs Drug: Standard treatment of Covid-19 |
Phase 2 | Stem Cell and Cancer Research Indonesia, Provincial Government of Central Java, Indonesia | NETWORK | 48 | All | RSUD Bantul, Bantul, Central Java, Indonesia RS PKU Muhammadiyah Gamping, Yogyakarta, Central Java, Indonesia RS Primaya Bekasi Timur, Bekasi, Jakarta, Indonesia Bhayangkara Hospital, Makassar, South Celebes, Indonesia Gatot Soebroto Army Hospital, Jakarta, Indonesia Dr. Esnawan Antariksa Air Force Hospital, Jakarta, Indonesia |
|
106 | Recruiting | Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV) | COVID-19 Pneumonia | Biological: Mesenchymal Stromal Cells Other: Placebo |
Phase 2 | Red de Terapia Celular, Citospin, University of Valladolid, Castilla-Leon Health Service, Hospital del Rio Hortega, Instituto de Salud Carlos III | INDUSTRY | 24 | All | 18 Years | Hospital Universitario Rio Hortega, Valladolid, Spain |
105 | Not yet recruiting | TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19 | Covid19 | Biological: Anti-SARS-CoV-2 immunoglobulin | Phase 2 | D'Or Institute for Research and Education | OTHER | 41 | All | 18 Years ~ 75 Years | |
104 | Completed | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | Coronavirus Disease 2019 (COVID-19) | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody Drug: Placebo |
Phase 2 | CSL Behring | INDUSTRY | 124 | All | 18 Years | Nova Clinical Research, LLC, Bradenton, Florida, United States Theia Clinical Research, LLC, Saint Petersburg, Florida, United States MercyOne North Iowa Medical Center, Mason City, Iowa, United States Northeast Iowa Medical Education Foundation, Waterloo, Iowa, United States Lahey Hospital and Medical Center, Burlington, Massachusetts, United States University of Mississippi Medical Center, Jackson, Mississippi, United States Holy Name Hospital, Teaneck, New Jersey, United States Inspira Health Center Vineland, Vineland, New Jersey, United States Sisters of Charity Hospital/ St. Joseph's Campus, Buffalo, New York, United States Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States Monument Health Clinical Research, Rapid City, South Dakota, United States PharmaTex Research, Amarillo, Texas, United States UT Health Science Center, McGovern Medical School, Houston, Texas, United States Inova Alexandria Hospital, Alexandria, Virginia, United States |
103 | Completed | Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) | Corona Virus Disease 2019(COVID-19) | Biological: UC-MSCs Biological: Saline containing 1% Human serum albumin(solution without UC-MSCs) |
Phase 2 | Beijing 302 Hospital, Huoshenshan Hospital, Maternal and Child Health Hospital of Hubei Province, The General Hospital of Central Theater Command, VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China | OTHER | 100 | All | 18 Years ~ 75 Years | General Hospital of Central Theater Command, Wuhan, Hubei, China Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China Wuhan Huoshenshan Hospital, Wuhan, Hubei, China |
102 | Recruiting | Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19 | COVID-19 | Drug: Convalescent Plasma | Phase 2 | University of New Mexico | OTHER | 30 | All | 18 Years | University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States |
101 | Recruiting | Treatment With Pirfenidone for COVID-19 Related Severe ARDS | ARDS | Drug: Pirfenidone Other: Standard of care |
Not Applicable | Soroka University Medical Center, Roche Pharma AG | OTHER | 100 | All | 18 Years ~ 80 Years | Soroka Medical Center, Be'er Sheva, Israel |